On the recordSeptember 16, 2015
Given the similarity between FDA's draft guidance and the World Health Organization's scheme on biologics qualifiers, it would be important to consult with a WHO in arriving at a global solution.
Source
congress.govGiven the similarity between FDA's draft guidance and the World Health Organization's scheme on biologics qualifiers, it would be important to consult with a WHO in arriving at a global solution.
Senator Hatch emphasizes the need for global consultation with WHO on drug naming.
Share
More from Orrin Hatch
It is disappointing the ranking member feels a need to question a statement that I made during the hearing.